clinical trial · NCT07219966
A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder
Eli Lilly and Company·phase3·recruiting·n = 1,100
Alcohol Use DisorderLY3537031Placebo
brief summary
The purpose of this study is to see if brenipatide when compared to a placebo works and is safe for participants with moderate-to-severe Alcohol Use Disorder (AUD). Participation in this study will last approximately 56 weeks.
started
Oct 15, 2025
primary completion
Apr 1, 2028
completion
Apr 1, 2028
last updated
May 14, 2026
official title
A Phase 3, Multicenter, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Brenipatide Compared With Placebo for the Treatment of Adult Participants With Moderate-to-Severe Alcohol Use Disorder (RENEW-ALC-1)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol